Insurance Rejections and High Costs Block Blood Cancer Patients From Filling Vital Oral Drug Prescriptions

Oral anticancer medications have quietly revolutionized the treatment of blood cancers over the past two decades. Pills that patients can swallow at home now offer highly effective, targeted options for leukemias, lymphomas, and multiple myeloma, replacing or complementing intravenous chemotherapy regimens that once required frequent hospital visits. Yet a new nationwide analysis from researchers at the Perelman School of Medicine at the University of Pennsylvania suggests that the journey from a physician’s prescription to a filled bottle at the pharmacy counter is far more treacherous than the science behind these drugs might imply. The study, published in the Journal of Clinical Oncology and funded by Blood Cancer United, formerly the Leukemia & Lymphoma Society, provides one of the most detailed portraits to date of how insurance design shapes whether patients with blood cancers actually receive the medications their doctors believe will prolong their lives.

The research team, working in collaboration with investigators from MD Anderson Cancer Center, Yale University, and Columbia University, tracked more than 12,000 prescriptions for oral blood cancer drugs in 2022 among patients insured through Medicare or commercial health plans. Rather than simply measuring whether patients eventually obtained their medications, the investigators followed each prescription along a complete pathway: from the initial submission at the pharmacy, through the insurer’s approval or rejection decision, to whether the patient ultimately filled the prescription within 90 days. This longitudinal design allowed the researchers to quantify not just a single barrier but a cascade of them, revealing two distinct points at which patients fall away from treatment.

The first drop-off occurs at the pharmacy counter before treatment even begins. At the initial submission, 64.9 percent of prescriptions for Medicare patients and a striking 84 percent of prescriptions for commercially insured patients were rejected by insurers. The most common reasons were prior authorization requirements, in which a prescriber must submit additional documentation to justify the drug, and outright non-coverage, in which the medication simply was not included in the patient’s plan formulary. Among Medicare beneficiaries, 32.1 percent of prescriptions were initially rejected because prior authorization was required, while among commercially insured patients, 27.8 percent were rejected for prior authorization and 17.1 percent because the drug was not covered at all.

Time and persistence resolved many of these rejections. Within 90 days, the share of prescriptions still rejected had fallen dramatically: insurer approval rates climbed to 85 percent for Medicare patients and 62.9 percent for commercially insured patients. Prior authorization rejections in particular proved largely surmountable, falling from 32.1 percent to just 4.6 percent among Medicare patients, and from 27.8 percent to 6.9 percent among commercially insured patients. Non-coverage rejections also declined, dropping to 8.0 percent in the commercial group. The researchers caution that they could not determine whether any individual rejection was clinically appropriate, but the pattern is telling: when insurers that initially refused a drug ultimately approve the very same therapy, the initial refusal appears to have imposed administrative work and treatment delay without changing the clinical outcome.

For patients with aggressive blood cancers, such delays are not trivial. Targeted oral therapies for chronic myeloid leukemia, for example, work best when started promptly, and clinicians generally regard rapid treatment initiation as essential for diseases that can progress over weeks or months. Every day spent navigating paperwork is a day the underlying malignancy continues to advance. The study’s authors argue that the sheer volume of initial rejections, most of which are later reversed, suggests that prior authorization may function less as a clinical safeguard and more as a friction-generating gatekeeper, one whose costs are borne by patients, oncology practices, and pharmacy staff alike.

The second drop-off is financial, and it occurs after the insurer has said yes. Even with approval in hand, only 54.5 percent of Medicare patients and 45.5 percent of commercially insured patients had a prescription that was both approved and filled within 90 days. The analysis found a steep, nearly linear relationship between out-of-pocket cost and the likelihood that a patient would actually fill the prescription. Among Medicare beneficiaries, fill rates were 84.9 percent when out-of-pocket costs were 15 dollars or less, and 76.7 percent when costs ranged from just over 15 dollars to 175 dollars. But when costs climbed into the 175-to-500-dollar range, fill rates collapsed to 38 percent, and they fell further to 29.2 percent when costs ranged from just over 500 dollars to 2,000 dollars.

Commercially insured patients showed the same pattern, with even steeper penalties at the high end. Fill rates were 80 percent when out-of-pocket costs were 15 dollars or less and 71.3 percent in the 15-to-175-dollar band, but only 30.9 percent when costs ranged from just over 500 to 2,000 dollars, and a mere 21.6 percent when costs exceeded 2,000 dollars. In other words, roughly four out of five patients facing modest copays filled their prescriptions, while fewer than one in four did so when confronted with four-figure cost-sharing. Because specialty oral anticancer drugs are typically covered under pharmacy benefits rather than medical benefits, patients encounter these cost-sharing requirements directly and often unexpectedly, sometimes at the very moment they are processing a frightening new diagnosis.

Senior author Jalpa A. Doshi, the Leon Hess Professor of Internal Medicine and a senior fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania, framed the findings as a map of where the prescription pathway fails. She noted that these blood cancer medications can be life-prolonging, but that insurance coverage requirements and high out-of-pocket costs can delay or limit access, and that the national benchmark her team constructed helps identify exactly where patients encounter barriers along the way. Doshi also emphasized that getting an insurer to approve a cancer drug is only the first hurdle, describing a second drop-off at the pharmacy counter when patients face high out-of-pocket costs. For Medicare beneficiaries, she pointed to the new annual out-of-pocket cost cap and the Medicare Prescription Payment Plan, which allows patients to spread prescription costs across the year, as potentially meaningful relief, though she stressed that awareness and enrollment will be critical if patients are to benefit.

The comparison between insurance types carries its own policy implications. Commercially insured patients fared worse on nearly every measure: higher initial rejection rates, lower final approval rates, and lower combined approval-and-fill rates. The authors suggest that reforms to prior authorization processes, drug coverage rules, and cost-sharing structures may be needed to ensure that a patient’s access to oral cancer drugs is not determined by the arbitrary design of the insurance plan they happen to hold. Such reforms could include standardizing and expediting prior authorization for oncology medications, requiring formularies to cover at least one drug within each therapeutic class, and capping specialty drug cost-sharing for commercially insured patients in ways that mirror the protections now phasing in for Medicare.

For a field that has celebrated the scientific triumph of targeted oral oncology, the study is a sobering reminder that a molecule’s efficacy is meaningless if it never reaches the bloodstream. The technical achievements are real: kinase inhibitors, immunomodulators, and proteasome inhibitors taken as daily pills have converted once-fatal diagnoses into manageable chronic conditions for many patients. But the delivery system wrapped around those molecules, with its prior authorization forms, formulary exclusions, and deductible-driven cost-sharing, is failing a substantial fraction of the very patients the drugs were designed to help. The Penn-led analysis turns that failure into measurable, comparable numbers, giving policymakers, insurers, and advocacy organizations a concrete benchmark against which future reforms, from streamlined authorization to expanded payment plans, can be judged. Whether the next generation of blood cancer patients will face the same gauntlet will depend on how quickly those reforms move from the pages of journals into the mechanics of insurance plans.

Subject of Research: Insurance coverage barriers and out-of-pocket costs affecting access to oral blood cancer medications

Article Title: Insurance barriers limit access to blood cancer drugs

Article References: Insurance barriers limit access to blood cancer drugs. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: blood cancer, oral anticancer drugs, prior authorization, insurance coverage, out-of-pocket costs, Medicare, prescription fill rates, leukemia, lymphoma, multiple myeloma, pharmacy benefits, health policy